Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Umbilical cord transplantation

J E Wagner1

  • 1University of Minnesota, Minneapolis 55455, USA.

Leukemia
|October 20, 1998
PubMed
Summary
This summary is machine-generated.

Umbilical cord blood transplants (UCBT) show high engraftment rates and faster neutrophil recovery compared to traditional bone marrow transplants. UCBT offers advantages like reduced graft-versus-host disease risk and quicker transplant intervals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytomegalovirus-Specific Immunity Recovers More Slowly after Cord Blood Transplantation Compared with Matched Sibling Donor Allogeneic Transplantation.

Transplantation and cellular therapy·2021
Same author

Bone marrow transplant with post-transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts.

The British journal of dermatology·2019
Same author

In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Ovarian function after hematopoietic cell transplantation: a descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning.

Bone marrow transplantation·2016
Same author

Investigation of the 3-D actinic flux field in mountainous terrain.

Atmospheric research·2015
Same author

The effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AML.

Bone marrow transplantation·2014
Same journal

Linperlisib enhances MUC1-Tn CAR T cell efficacy by inhibiting EGR1/DUSP2 axis to prevent CAR T cell exhaustion.

Leukemia·2026
Same journal

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

Leukemia·2026
Same journal

Single-cell architecture of purinergic signaling in human cord blood hematopoietic stem and progenitor cells.

Leukemia·2026
Same journal

Feasibility and safety of rapid glofitamab ramp-up.

Leukemia·2026
Same journal

Single-cell DNA methylation analysis uncovers epigenetic pathways in the transformation of MDS to AML.

Leukemia·2026
Same journal

PD-L2 is associated with lineage-related transcriptional programs distinct from PD-L1 in primary mediastinal large B-cell lymphoma.

Leukemia·2026
See all related articles

Area of Science:

  • Hematology
  • Transplantation Immunology

Background:

  • Allogeneic bone marrow transplantation faces challenges including donor matching difficulties, graft failure, graft-versus-host disease (GVHD), and infections.
  • Umbilical cord blood (UCB) presents a potential alternative to overcome these limitations.

Purpose of the Study:

  • To evaluate the clinical efficacy and outcomes of umbilical cord blood transplants (UCBT).
  • To compare UCBT with traditional bone marrow transplantation.

Main Methods:

  • Phase I-II clinical trials were conducted to assess UCBT.
  • Engraftment rates, time to neutrophil recovery, GVHD incidence, and survival were analyzed.
  • Factors influencing engraftment and survival, including HLA matching and cell dose, were investigated.

Related Experiment Videos

Main Results:

  • UCBT demonstrated an approximate 90% engraftment rate with a median neutrophil recovery time of 26 days.
  • Nucleated cell dose, CFU-GM, and CD34+ content inversely correlated with neutrophil recovery time (P < .01).
  • Grade II-IV GVHD occurred in approximately 40% of patients, irrespective of HLA disparity. Age and cell dose were predictive of survival in HLA 0-2 disparities. HLA matching did not significantly impact engraftment, GVHD risk, or survival.

Conclusions:

  • UCBT offers significant advantages over bone marrow transplants for hematopoietic reconstitution.
  • These advantages include shorter transplant intervals, no donor attrition, no harvest complications, and a very low risk of cytomegalovirus transmission.